 | • レポートコード：MRC309Z7922 • 出版社/出版日：GlobalInfoResearch / 2023年9月 • レポート形態：英文、PDF、100ページ • 納品方法：Eメール（2-3営業日） • 産業分類：医薬品＆ヘルスケア |
| Single User | ￥522,000 (USD3,480) | ▷ お問い合わせ |
| Corporate User | ￥1,044,000 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| GlobalInfoResearchの最新の調査によると、世界の麻疹弱毒生ワクチンの市場規模は2022年のxxx米ドルから2029年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を考慮しながら市場規模を推計しました。 このレポートは、世界の麻疹弱毒生ワクチン市場に関する詳細かつ包括的な分析の結果です。定量的分析と定性的分析データが、メーカー別、地域別、国別、種類別、用途別に記載されています。 市場は常に変化しているため、本レポートでは、競争、需要と供給の傾向、および多くの市場にわたる需要の変化に影響する主要な要因を調査しました。主要な競合他社の企業概要と製品例、および2023年の市場シェア予測も記載しました。 本レポートの主な目的は次のとおりです。 - 世界および主要国の市場機会の規模を決定するため - 麻疹弱毒生ワクチンの成長可能性を評価するため - 各製品および最終用途市場の将来の成長を予測するため - 市場に影響を与える競争要因を評価するため 麻疹弱毒生ワクチン市場は種類と用途によって区分されます。2018年～2029年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。 種類別セグメント ・粉末、液体 用途別セグメント ・病院、診療所 主要な市場プレーヤー ・Merck、Pfizer、Serum Institute of India、GSK、Sanofi-Pasteur、Novartis、Bavarian Nordic、Medimmune、Changchun Keygen Biological Products、Shanghai Institute of Biological Products、Wuhan Institute of Biological Products、Lanzhou Institute of Biological Products 地域別セグメントは次の地域・国をカバーします。 ・北米（米国、カナダ、メキシコ） ・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア） ・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア） ・南アメリカ（ブラジル、アルゼンチン、コロンビア） ・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ） 本調査レポートの内容は計15章あります。 ・第1章では、麻疹弱毒生ワクチン製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。 ・第2章では、主要な麻疹弱毒生ワクチンメーカーの企業概要、2019年～2022年までの麻疹弱毒生ワクチンの価格、販売量、売上、市場シェアを掲載しています。 ・第3章では、主要な麻疹弱毒生ワクチンメーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。 ・第4章では、2018年～2029年までの地域別麻疹弱毒生ワクチンの販売量、売上、成長性を示しています。 ・第5、6章では、2018年～2029年までの麻疹弱毒生ワクチンの種類別と用途別の市場規模、市場シェアと成長率を掲載しています。 ・第7、8、9、10、11章では、2018年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2029年までの主要地域での麻疹弱毒生ワクチン市場予測を収録しています。 ・第12章では、市場力学、成長要因、阻害要因、トレンド、ポーターズファイブフォース分析、新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を掲載しています。 ・第13章では、主要な原材料、主要なサプライヤー、および麻疹弱毒生ワクチンの産業チェーンを掲載しています。 ・第14、15章では、麻疹弱毒生ワクチンの販売チャネル、販売業者、顧客、調査結果について説明します。 ***** 目次(一部) ***** ・市場概要 - 麻疹弱毒生ワクチンの概要 - 種類別分析（2018年vs2022年vs2029年）：粉末、液体 - 用途別分析（2018年vs2022年vs2029年）：病院、診療所 - 世界の麻疹弱毒生ワクチン市場規模・予測 - 世界の麻疹弱毒生ワクチン生産能力分析 - 市場の成長要因・阻害要因・動向 ・メーカー情報（企業概要、製品概要、販売量、価格、売上） - Merck、Pfizer、Serum Institute of India、GSK、Sanofi-Pasteur、Novartis、Bavarian Nordic、Medimmune、Changchun Keygen Biological Products、Shanghai Institute of Biological Products、Wuhan Institute of Biological Products、Lanzhou Institute of Biological Products ・メーカー別市場シェア・市場集中度 ・地域別市場分析2018年-2029年 ・種類別分析2018年-2029年：粉末、液体 ・用途別分析2018年-2029年：病院、診療所 ・麻疹弱毒生ワクチンの北米市場 - 種類別市場規模2018年-2029年 - 用途別市場規模2018年-2029年 - 主要国別市場規模：アメリカ、カナダ、メキシコなど ・麻疹弱毒生ワクチンのヨーロッパ市場 - 種類別市場規模2018年-2029年 - 用途別市場規模2018年-2029年 - 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど ・麻疹弱毒生ワクチンのアジア市場 - 種類別市場規模2018年-2029年 - 用途別市場規模2018年-2029年 - 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど ・麻疹弱毒生ワクチンの南米市場 - 種類別市場規模2018年-2029年 - 用途別市場規模2018年-2029年 - 主要国別市場規模：ブラジル、アルゼンチンなど ・麻疹弱毒生ワクチンの中東・アフリカ市場 - 種類別市場規模2018年-2029年 - 用途別市場規模2018年-2029年 - 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど ・市場力学（成長要因、阻害要因、トレンド、ポーターズファイブフォース分析） ・原材料および産業チェーン ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
According to our (Global Info Research) latest study, the global Measles Attenuated Live Vaccine market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
This report is a detailed and comprehensive analysis for global Measles Attenuated Live Vaccine market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Measles Attenuated Live Vaccine market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Measles Attenuated Live Vaccine market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Measles Attenuated Live Vaccine market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Measles Attenuated Live Vaccine market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023.
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Measles Attenuated Live Vaccine
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace.
This report profiles key players in the global Measles Attenuated Live Vaccine market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Merck, Pfizer, Serum Institute of India, GSK and Sanofi-Pasteur, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
Measles Attenuated Live Vaccine market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Powder
Liquid
Market segment by Application
Hospital
Clinic
Major players covered
Merck
Pfizer
Serum Institute of India
GSK
Sanofi-Pasteur
Novartis
Bavarian Nordic
Medimmune
Changchun Keygen Biological Products
Shanghai Institute of Biological Products
Wuhan Institute of Biological Products
Lanzhou Institute of Biological Products
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Measles Attenuated Live Vaccine product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Measles Attenuated Live Vaccine, with price, sales, revenue and global market share of Measles Attenuated Live Vaccine from 2018 to 2023.
Chapter 3, the Measles Attenuated Live Vaccine competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Measles Attenuated Live Vaccine breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Measles Attenuated Live Vaccine market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Measles Attenuated Live Vaccine.
Chapter 14 and 15, to describe Measles Attenuated Live Vaccine sales channel, distributors, customers, research findings and conclusion.
1 Market Overview
1.1 Product Overview and Scope of Measles Attenuated Live Vaccine
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Measles Attenuated Live Vaccine Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Powder
1.3.3 Liquid
1.4 Market Analysis by Application
1.4.1 Overview: Global Measles Attenuated Live Vaccine Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Hospital
1.4.3 Clinic
1.5 Global Measles Attenuated Live Vaccine Market Size & Forecast
1.5.1 Global Measles Attenuated Live Vaccine Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Measles Attenuated Live Vaccine Sales Quantity (2018-2029)
1.5.3 Global Measles Attenuated Live Vaccine Average Price (2018-2029)
2 Manufacturers Profiles
2.1 Merck
2.1.1 Merck Details
2.1.2 Merck Major Business
2.1.3 Merck Measles Attenuated Live Vaccine Product and Services
2.1.4 Merck Measles Attenuated Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Merck Recent Developments/Updates
2.2 Pfizer
2.2.1 Pfizer Details
2.2.2 Pfizer Major Business
2.2.3 Pfizer Measles Attenuated Live Vaccine Product and Services
2.2.4 Pfizer Measles Attenuated Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Pfizer Recent Developments/Updates
2.3 Serum Institute of India
2.3.1 Serum Institute of India Details
2.3.2 Serum Institute of India Major Business
2.3.3 Serum Institute of India Measles Attenuated Live Vaccine Product and Services
2.3.4 Serum Institute of India Measles Attenuated Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Serum Institute of India Recent Developments/Updates
2.4 GSK
2.4.1 GSK Details
2.4.2 GSK Major Business
2.4.3 GSK Measles Attenuated Live Vaccine Product and Services
2.4.4 GSK Measles Attenuated Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 GSK Recent Developments/Updates
2.5 Sanofi-Pasteur
2.5.1 Sanofi-Pasteur Details
2.5.2 Sanofi-Pasteur Major Business
2.5.3 Sanofi-Pasteur Measles Attenuated Live Vaccine Product and Services
2.5.4 Sanofi-Pasteur Measles Attenuated Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Sanofi-Pasteur Recent Developments/Updates
2.6 Novartis
2.6.1 Novartis Details
2.6.2 Novartis Major Business
2.6.3 Novartis Measles Attenuated Live Vaccine Product and Services
2.6.4 Novartis Measles Attenuated Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Novartis Recent Developments/Updates
2.7 Bavarian Nordic
2.7.1 Bavarian Nordic Details
2.7.2 Bavarian Nordic Major Business
2.7.3 Bavarian Nordic Measles Attenuated Live Vaccine Product and Services
2.7.4 Bavarian Nordic Measles Attenuated Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Bavarian Nordic Recent Developments/Updates
2.8 Medimmune
2.8.1 Medimmune Details
2.8.2 Medimmune Major Business
2.8.3 Medimmune Measles Attenuated Live Vaccine Product and Services
2.8.4 Medimmune Measles Attenuated Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Medimmune Recent Developments/Updates
2.9 Changchun Keygen Biological Products
2.9.1 Changchun Keygen Biological Products Details
2.9.2 Changchun Keygen Biological Products Major Business
2.9.3 Changchun Keygen Biological Products Measles Attenuated Live Vaccine Product and Services
2.9.4 Changchun Keygen Biological Products Measles Attenuated Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Changchun Keygen Biological Products Recent Developments/Updates
2.10 Shanghai Institute of Biological Products
2.10.1 Shanghai Institute of Biological Products Details
2.10.2 Shanghai Institute of Biological Products Major Business
2.10.3 Shanghai Institute of Biological Products Measles Attenuated Live Vaccine Product and Services
2.10.4 Shanghai Institute of Biological Products Measles Attenuated Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Shanghai Institute of Biological Products Recent Developments/Updates
2.11 Wuhan Institute of Biological Products
2.11.1 Wuhan Institute of Biological Products Details
2.11.2 Wuhan Institute of Biological Products Major Business
2.11.3 Wuhan Institute of Biological Products Measles Attenuated Live Vaccine Product and Services
2.11.4 Wuhan Institute of Biological Products Measles Attenuated Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Wuhan Institute of Biological Products Recent Developments/Updates
2.12 Lanzhou Institute of Biological Products
2.12.1 Lanzhou Institute of Biological Products Details
2.12.2 Lanzhou Institute of Biological Products Major Business
2.12.3 Lanzhou Institute of Biological Products Measles Attenuated Live Vaccine Product and Services
2.12.4 Lanzhou Institute of Biological Products Measles Attenuated Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Lanzhou Institute of Biological Products Recent Developments/Updates
3 Competitive Environment: Measles Attenuated Live Vaccine by Manufacturer
3.1 Global Measles Attenuated Live Vaccine Sales Quantity by Manufacturer (2018-2023)
3.2 Global Measles Attenuated Live Vaccine Revenue by Manufacturer (2018-2023)
3.3 Global Measles Attenuated Live Vaccine Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Measles Attenuated Live Vaccine by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Measles Attenuated Live Vaccine Manufacturer Market Share in 2022
3.4.2 Top 6 Measles Attenuated Live Vaccine Manufacturer Market Share in 2022
3.5 Measles Attenuated Live Vaccine Market: Overall Company Footprint Analysis
3.5.1 Measles Attenuated Live Vaccine Market: Region Footprint
3.5.2 Measles Attenuated Live Vaccine Market: Company Product Type Footprint
3.5.3 Measles Attenuated Live Vaccine Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Measles Attenuated Live Vaccine Market Size by Region
4.1.1 Global Measles Attenuated Live Vaccine Sales Quantity by Region (2018-2029)
4.1.2 Global Measles Attenuated Live Vaccine Consumption Value by Region (2018-2029)
4.1.3 Global Measles Attenuated Live Vaccine Average Price by Region (2018-2029)
4.2 North America Measles Attenuated Live Vaccine Consumption Value (2018-2029)
4.3 Europe Measles Attenuated Live Vaccine Consumption Value (2018-2029)
4.4 Asia-Pacific Measles Attenuated Live Vaccine Consumption Value (2018-2029)
4.5 South America Measles Attenuated Live Vaccine Consumption Value (2018-2029)
4.6 Middle East and Africa Measles Attenuated Live Vaccine Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Measles Attenuated Live Vaccine Sales Quantity by Type (2018-2029)
5.2 Global Measles Attenuated Live Vaccine Consumption Value by Type (2018-2029)
5.3 Global Measles Attenuated Live Vaccine Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Measles Attenuated Live Vaccine Sales Quantity by Application (2018-2029)
6.2 Global Measles Attenuated Live Vaccine Consumption Value by Application (2018-2029)
6.3 Global Measles Attenuated Live Vaccine Average Price by Application (2018-2029)
7 North America
7.1 North America Measles Attenuated Live Vaccine Sales Quantity by Type (2018-2029)
7.2 North America Measles Attenuated Live Vaccine Sales Quantity by Application (2018-2029)
7.3 North America Measles Attenuated Live Vaccine Market Size by Country
7.3.1 North America Measles Attenuated Live Vaccine Sales Quantity by Country (2018-2029)
7.3.2 North America Measles Attenuated Live Vaccine Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Measles Attenuated Live Vaccine Sales Quantity by Type (2018-2029)
8.2 Europe Measles Attenuated Live Vaccine Sales Quantity by Application (2018-2029)
8.3 Europe Measles Attenuated Live Vaccine Market Size by Country
8.3.1 Europe Measles Attenuated Live Vaccine Sales Quantity by Country (2018-2029)
8.3.2 Europe Measles Attenuated Live Vaccine Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Measles Attenuated Live Vaccine Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Measles Attenuated Live Vaccine Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Measles Attenuated Live Vaccine Market Size by Region
9.3.1 Asia-Pacific Measles Attenuated Live Vaccine Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Measles Attenuated Live Vaccine Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Measles Attenuated Live Vaccine Sales Quantity by Type (2018-2029)
10.2 South America Measles Attenuated Live Vaccine Sales Quantity by Application (2018-2029)
10.3 South America Measles Attenuated Live Vaccine Market Size by Country
10.3.1 South America Measles Attenuated Live Vaccine Sales Quantity by Country (2018-2029)
10.3.2 South America Measles Attenuated Live Vaccine Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Measles Attenuated Live Vaccine Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Measles Attenuated Live Vaccine Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Measles Attenuated Live Vaccine Market Size by Country
11.3.1 Middle East & Africa Measles Attenuated Live Vaccine Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Measles Attenuated Live Vaccine Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Measles Attenuated Live Vaccine Market Drivers
12.2 Measles Attenuated Live Vaccine Market Restraints
12.3 Measles Attenuated Live Vaccine Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Measles Attenuated Live Vaccine and Key Manufacturers
13.2 Manufacturing Costs Percentage of Measles Attenuated Live Vaccine
13.3 Measles Attenuated Live Vaccine Production Process
13.4 Measles Attenuated Live Vaccine Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Measles Attenuated Live Vaccine Typical Distributors
14.3 Measles Attenuated Live Vaccine Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer